» Articles » PMID: 10914553

Protease Inhibitor-induced Apoptosis: Accumulation of Wt P53, P21WAF1/CIP1, and Induction of Apoptosis Are Independent Markers of Proteasome Inhibition

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2000 Jul 29
PMID 10914553
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Inhibitors of proteases are currently emerging as a potential anti-cancer modality. Nonselective protease inhibitors are cytotoxic to leukemia and cancer cell lines and we found that this cytotoxicity is correlated with their potency as inhibitors of the proteasome but not as inhibitors of calpain and cathepsin. Highly selective inhibitors of the proteasome were more cytotoxic and fast-acting than less selective inhibitors (PS341>>ALLN>>ALLM). Induction of wt p53 correlated with inhibition of the proteasome and antiproliferative effect in MCF7, a breast cancer cell line, which was resistant to apoptosis caused by proteasome inhibitors. In contrast, inhibitors of the proteasome induced apoptosis in four leukemia cell lines lacking wt p53. The order of sensitivity of leukemia cells was: Jurkat>HL60> or =U937>>K562. The highly selective proteasome inhibitor PS-341 induced cell death with an IC50 as low as 5 nM in apoptosis-prone leukemia cells. Cell death was preceded by p21WAF1/CIP1 accumulation, an alternative marker of proteasome inhibition, and by cleavage of PARP and Rb proteins and nuclear fragmentation. Inhibition of caspases abrogated PARP cleavage and nuclear fragmentation and delayed, but did not completely prevent cell death caused by PS-341. Reintroduction of wt p53 into p53-null PC3 prostate carcinoma cells did not increase their sensitivity to proteasome inhibitors. Likewise, comparison of parental and p21-deficient cells demonstrated that p21WAF1/CIP1 was dispensable for proteasome inhibitor-induced cytotoxicity. We conclude that accumulation of wt p53 and induction of apoptosis are independent markers of proteasome inhibition.

Citing Articles

Structural Design, Anticancer Evaluation, and Molecular Docking of Newly Synthesized Ni(II) Complexes with -Donor Dithiocarbazate Ligands.

Gatto C, Cavalcante C, Lima F, Nascimento E, Martins J, Santana B Molecules. 2024; 29(12).

PMID: 38930825 PMC: 11206525. DOI: 10.3390/molecules29122759.


Modular Synthesis of Complex Benzoxaboraheterocycles through Chelation-Assisted Rh-Catalyzed [2 + 2 + 2] Cycloaddition.

Halford-McGuff J, Varga M, Cordes D, McKay A, Watson A ACS Catal. 2024; 14(3):1846-1854.

PMID: 38327642 PMC: 10845118. DOI: 10.1021/acscatal.3c05766.


Liposomes for Cancer Theranostics.

Fernandes D Pharmaceutics. 2023; 15(10).

PMID: 37896208 PMC: 10610083. DOI: 10.3390/pharmaceutics15102448.


RUNX3 Meets the Ubiquitin-Proteasome System in Cancer.

Toska A, Modi N, Chen L Cells. 2023; 12(5).

PMID: 36899853 PMC: 10001085. DOI: 10.3390/cells12050717.


The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Tundo G, Sbardella D, Santoro A, Coletta A, Oddone F, Grasso G Pharmacol Ther. 2020; 213:107579.

PMID: 32442437 PMC: 7236745. DOI: 10.1016/j.pharmthera.2020.107579.